Novartis signs licensing deal worth up to $7.8B with China's Abogen for mRNA therapies
The pact is one of the largest Western bets on Chinese RNA drug development and expands Novartis' pipeline beyond its existing areas.
medicaldialogues.in · +11 outlets
Trump announces $90 payments for seniors' Medicare Part B premiums ahead of midterms
The move directs money to older voters just before the Nov. 3 midterm elections and touches drug and coverage policy debates.
STAT · +14 outlets
FDA approves breakthrough drug to treat advanced pancreatic cancer
A new approval for advanced pancreatic cancer adds an option in a disease with historically poor survival.
CU Anschutz newsroom · +13 outlets
Eli Lilly gains FDA approval for Jaypirca
The approval adds to Lilly's oncology portfolio as it expands beyond its metabolic franchise.
Mugglehead Investment Magazine · +14 outlets
China's biotechs in Shanghai's 'Science City' pitch to global partners
Chinese biotechs are increasingly seeking overseas licensing deals, reshaping global drug development.
The Boston Globe · +2 outlets
Fate Therapeutics shares jump 6% as FDA clears cell therapy to enter clinical trials
The clearance moves an off-the-shelf cell therapy into human testing, a key milestone for the allogeneic approach.
Stocktwits · +1 outlets
Moleculin Biotech shares drop 25% after interim cancer trial data fall short of significance
The miss raises doubts about the registrational path for the company's lead cancer program.
Stocktwits · +2 outlets
Big pharma bets on KRAS G12D as oncology race intensifies
KRAS G12D is among the most sought-after oncology targets, with multiple large drugmakers competing.
Chosunbiz · +2 outlets
Manufacturers weigh in as FDA flags unapproved GLP-1 drugs used for weight loss
Regulators are scrutinizing compounded and unapproved GLP-1 products as demand for weight-loss drugs surges.
BusinessWorld Online · +10 outlets
Studies link sex chromosomes to cancer, heart health and longevity outcomes
The findings suggest biological sex differences should inform how diseases are studied and treated.
University of Arizona News · +14 outlets
Moderna stock under scrutiny as analysts ask whether rally makes it a sell
Moderna's shares have recovered from lows, prompting debate over valuation as COVID revenue declines.
TradingView
BioNTech moves past Covid as investors assess its post-pandemic pipeline
BioNTech's valuation increasingly hinges on oncology programs as COVID vaccine sales fade.
Seeking Alpha · +1 outlets
Ultragenyx says EMA validates MPS IIIA marketing application
Validation starts the EU review clock for a rare disease therapy, a key step toward potential approval.
Mugglehead Investment Magazine · +3 outlets
Arcus Biosciences rallies but questions over its pipeline remain open
The stock run has outpaced clarity on the company's clinical and commercial strategy.
Simply Wall Street · +1 outlets
Gamma delta T cells blur the line between innate and adaptive immunity
The biology of gamma delta T cells is drawing interest for next-generation cell therapies.
Bioengineer.org · +2 outlets
Engineered natural killer cells show potent activity against glioblastoma
NK cell engineering is emerging as a promising avenue in hard-to-treat brain tumors.
Bioengineer.org · +11 outlets
Analysts see continued opportunities in immuno-oncology as biotech ETF gains
Immuno-oncology remains a favored theme for investors even as the broader biotech sector swings.
Stocktwits
'Rogue DNA' helps some cancers thrive, and researchers find its Achilles' heel
Extrachromosomal DNA is a recognized driver of tumor evolution and drug resistance.
The Debrief